| Drug General Information |
| Drug ID |
D06REJ
|
| Former ID |
DIB015221
|
| Drug Name |
MX-7065
|
| Synonyms |
Cdc25 phosphatase inhibitors, Maxia Pharmaceuticals; MX-7065; MX-7102; MX-7174; MX-7214; MX-7306
|
| Indication |
Cancer [ICD9: 140-229; ICD10:C00-C96]
|
Terminated |
[1]
|
|---|
| Company |
Maxia Pharmaceuticals Inc
|
| Target and Pathway |
| Target(s) |
M-phase inducer phosphatase 3 |
Target Info |
Inhibitor |
[2]
|
|---|
| M-phase inducer phosphatase 1 |
Target Info |
Inhibitor |
[2]
|
| M-phase inducer phosphatase 2 |
Target Info |
Inhibitor |
[2]
|
|
KEGG Pathway
|
Cell cycle
|
|
Oocyte meiosis
|
|
Progesterone-mediated oocyte maturation
|
|
MicroRNAs in cancerhsa04110:Cell cycle
|
|
MicroRNAs in cancerhsa04010:MAPK signaling pathway
|
|
MicroRNAs in cancer
|
|
NetPath Pathway
|
IL4 Signaling Pathway
|
|
TGF_beta_Receptor Signaling PathwayNetPath_14:IL2 Signaling Pathway
|
|
TGF_beta_Receptor Signaling Pathway
|
|
Wnt Signaling Pathway
|
|
PANTHER Pathway
|
p53 pathway
|
|
Pathway Interaction Database
|
ATR signaling pathway
|
|
ATM pathway
|
|
PLK1 signaling events
|
|
PLK3 signaling eventse2f_pathway:E2F transcription factor network
|
|
Validated targets of C-MYC transcriptional activation
|
|
ATM pathwayplk1_pathway:PLK1 signaling events
|
|
FOXM1 transcription factor network
|
|
p38 signaling mediated by MAPKAP kinases
|
|
Aurora A signaling
|
|
Reactome
|
Polo-like kinase mediated events
|
|
Cyclin B2 mediated events
|
|
Activation of ATR in response to replication stress
|
|
RHO GTPases activate PKNs
|
|
Cyclin A/B1 associated events during G2/M transition
|
|
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complexR-HSA-113510:E2F mediated regulation of DNA replication
|
|
G0 and Early G1
|
|
Cyclin E associated events during G1/S transition
|
|
G1/S-Specific Transcription
|
|
Ubiquitin Mediated Degradation of Phosphorylated Cdc25A
|
|
Cyclin A:Cdk2-associated events at S phase entryR-HSA-157881:Cyclin B2 mediated events
|
|
Cyclin A:Cdk2-associated events at S phase entry
|
|
WikiPathways
|
Monoamine Transport
|
|
DNA Damage Response
|
|
ATM Signaling Pathway
|
|
Integrated Pancreatic Cancer Pathway
|
|
Mitotic G2-G2/M phases
|
|
Cell Cycle
|
|
Cell Cycle Checkpoints
|
|
miRNA Regulation of DNA Damage ResponseWP707:DNA Damage Response
|
|
G1 to S cell cycle control
|
|
S Phase
|
|
Retinoblastoma (RB) in Cancer
|
|
Prostate Cancer
|
|
Integrated Breast Cancer Pathway
|
|
Integrated Cancer pathway
|
|
Mitotic G1-G1/S phases
|
|
miRNAs involved in DNA damage response
|
|
miRNA Regulation of DNA Damage ResponseWP615:Senescence and Autophagy in Cancer
|
|
MAPK Signaling Pathway
|
| References |
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016615) |
|---|
| REF 2 | Handbook of Assay Development in Drug Discovery, Lisa K. Minor, 2013. Page(11). |
|---|
